In total, COL4A3 sequencing was performed in 1631 patients: in 311 as part of the nephrotic syndrome panel, in 606 as part of the FSGS panel, in 579 as part of the Alport panel, and in 135, COL4A3 sequencing was included for other suspected genetic renal diseases. This evidence concerns the gene COL4A3 and nephrotic syndrome.